Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHTEN-Cirrhosis
2023-510395-31-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Oct 2024
- Modality
- Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Pegozafermin with Placebo (2 arms). Primary endpoints: Fibrosis regression at interim analysis and Time to first disease progression event. Planned start Oct 2024; status: authorised.
02
Drugs
pegozafermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2023-510395-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510395-31-00.